Abstract
The prevalence of dengue fever (DF) in many countries has become a global burden. The pathogen, dengue virus (DENV) contains four serotypes, and oftentimes the antibody-dependent enhancement (ADE) due to the insufficient and imbalanced host immunity leads to severe dengue symptoms in heterologous secondary infections, posing a major difficulty ahead of modern medicine. Two technical routes, vaccine and monoclonal antibody (mAb) have been widely explored and testified at various levels. Tetravalent vaccines, especially chimeric live-attenuated viruses (LAV), have been proven to induce a relatively well-rounded immune response, while other categories including virus-like particle (VLP) are also of high potential. Therapeutic mAbs also have been shown to target epitopes that can be cross-neutralizing, covering not only individual structural and non-structural proteins but also quaternary conformation of virion surface. Undoubtedly limitations of previous research have directed the refinement of vector design, efficacy assessment, and other processes, although several challenges still exist today.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
